Vordenbäumen S, Schinner S, Halle M, Fischer-Betz R, Schneider M
Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Deutschland.
Z Rheumatol. 2010 Oct;69(8):689-92, 694-5. doi: 10.1007/s00393-009-0586-4.
Cardiovascular diseases are the main cause of death worldwide and dyslipidemia constitutes a substantial risk factor. Patients with rheumatic diseases, especially active inflammatory arthritis and systemic lupus erythematosus, show unfavorable lipid profiles, which, however, do not account for the total excess cardiovascular morbidity. Effective disease management, life-style changes and cholesterol-lowering agents can ameliorate the lipid profile and lower cardiovascular mortality. Due to their anti-inflammatory and potent cholesterol-lowering properties, statins are the pharmacological agents of first choice. National and international guidelines on cardiovascular risk prevention differ concerning appraisal of the individual risk and lipid targets. The EULAR recently released recommendations for cardiovascular risk management in patients with inflammatory arthritis.
心血管疾病是全球主要死因，血脂异常是一个重要风险因素。患有风湿性疾病的患者，尤其是活动性炎症性关节炎和系统性红斑狼疮患者，血脂谱不理想，然而，这并不能解释心血管疾病总发病率的增加。有效的疾病管理、生活方式改变和降胆固醇药物可以改善血脂谱并降低心血管疾病死亡率。由于他汀类药物具有抗炎和强效降胆固醇特性，是首选的药物。关于个体风险评估和血脂目标，国家和国际心血管风险预防指南存在差异。欧洲抗风湿病联盟（EULAR）最近发布了炎症性关节炎患者心血管风险管理的建议。
